Your browser doesn't support javascript.
loading
Selected Aspects of the Analytical and Pharmaceutical Profiles of Nifurtimox.
Moroni, Aldana B; Calvo, Natalia L; Kaufman, Teodoro S.
Afiliación
  • Moroni AB; Área de Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario e Instituto de Química Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario S2002LRK, Argentina.
  • Calvo NL; Área de Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario e Instituto de Química Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario S2002LRK, Argentina.
  • Kaufman TS; Área de Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario e Instituto de Química Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario S2002LRK, Argentina. Electronic address: kaufman@iquir-conicet.gov.ar.
J Pharm Sci ; 112(6): 1523-1538, 2023 06.
Article en En | MEDLINE | ID: mdl-36822273
ABSTRACT
Nifurtimox is a nitroheterocyclic drug employed for treatment of trypanosomiases (Chagas disease and West African sleeping sickness); its use for certain cancers has also been assessed. Despite having been in the market for over 50 years, knowledge of nifurtimox is still fragmentary and incomplete. Relevant aspects of the chemistry and biology of nifurtimox are reviewed to summarize the current knowledge of this drug. These comprise its chemical synthesis and the preparation of some analogues, as well as its chemical degradation. Selected physical data and physicochemical properties are also listed, along with different approaches toward the analytical characterization of the drug, including electrochemical (polarography, cyclic voltammetry), spectroscopic (ultraviolet-visible, nuclear magnetic resonance, electron spin resonance), and single crystal X-ray diffractometry. The array of polarographic, ultraviolet-visible spectroscopic, and chromatographic methods available for the analytical determination of nifurtimox (in bulk drug, pharmaceutical formulations, and biological samples), are also presented and discussed, along with chiral chromatographic and electrophoretic alternatives for the separation of the enantiomers of the drug. Aspects of the drug likeliness of nifurtimox, its classification in the Biopharmaceutical Classification System, and available pharmaceutical formulations are detailed, whereas pharmacological, chemical, and biological aspects of its metabolism and disposition are discussed.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Farmacia / Enfermedad de Chagas Límite: Humans Idioma: En Revista: J Pharm Sci Año: 2023 Tipo del documento: Article País de afiliación: Argentina

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Farmacia / Enfermedad de Chagas Límite: Humans Idioma: En Revista: J Pharm Sci Año: 2023 Tipo del documento: Article País de afiliación: Argentina